search
Back to results

Linagliptin Add-on to Insulin Background Therapy

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
placebo
linagliptin
background therapy
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Diagnosis of type 2 diabetes mellitus prior to informed consent.
  • Chinese male or female patients who are pre-treated with insulin alone or in combination with metformin:

    • With maximum insulin dose of <= 1 unit/kg/day. Acceptable basal insulins could be insulin glargin, insulin detemir or NPH (neutral protamin hagedorn) insulin with duration of action up to 24 h; acceptable pre-mixed insulins could be preparations with 25/75 or 30/70 ratio, with once or twice daily posology only. The total insulin dose should not be changed by more than 10% of the baseline value within the 12 weeks prior to randomisation (Visit 3). Both human insulin & insulin analogue are accepted.
    • If the patient is taking metformin, stable dose (at least 1500 mg daily) must be maintained for at least 12 weeks without dose adjustments prior to randomisation (Visit 3).
  • HbA1c fulfills the following criteria: >= 7.5 % to <= 10.0 % at Visit 1.
  • Age >= 18 years at Visit 1.
  • BMI <= 45 kg/m2 (Body Mass Index) at Visit 1.
  • Women of childbearing potential must be ready and able to use highly effective methods of birth control per ICH (International Conference on Harmonisation) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.

    • A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile.
    • Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
  • Signed and dated written informed consent by date of Visit 1 in accordance with ICH-GCP (Good Clinical Practice) and local legislation

Exclusion criteria:

  • Uncontrolled hyperglycaemic with a glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day).
  • Any other antidiabetic drug within 3 months prior to informed consent except those defined as background treatment via inclusion criterion 2.
  • Acute coronary syndrome (non-STEMI (ST Segment Elevation Myocardial Infarction), STEMI and unstable angina pectoris), stroke or TIA (Transient ischemic attack) within 3 months prior to informed consent.
  • Indication of liver disease, defined by serum levels of either ALT (Alanine aminotransferase) (SGPT (serum glutamic pyruvate transaminase )), AST (Aspartate aminotransferase) (SGOT (serum glutamic-oxaloacetic transaminase)), or alkaline phosphatase above 3 × upper limit of normal (ULN (upper limit of normal)) as determined during screening and/or run-in phase.
  • Any contraindications to metformin according to the local label for those patients that enter the study with metformin therapy as provided in ISF (Investigator Site File).
  • Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption.
  • Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
  • Blood dyscrasias or any disorders causing hemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anemia).
  • Known hypersensitivity or allergy to the investigational product or its recipients.
  • Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight.
  • Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM (Type 2 diabetes mellitus).
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
  • Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator.
  • Participation in another trial with an investigational drug within 2 months prior to informed consent or previous enrolment in this trial.
  • Any other clinical condition that would jeopardize patient's safety while participating in this clinical trial in the opinion of the investigator.

Sites / Locations

  • China-Japan Friendship Hospital
  • Beijing Tongren Hospital
  • The General Hospital of Chinese People's Armed Police Forces
  • First Hospital of Jilin University
  • No.900 Hospital of PLA Joint Logistics Support Force
  • Third Affiliated Hospital of Guangzhou Medical University
  • The Affiliated Hospital of Guizhou Medical University
  • The Affiliated Hospital of Hangzhou Normal University
  • General Hospital of Jinan Military Area
  • Nanjing First Hospital
  • The affiliated hospital of medicalcollege qingdao university
  • Centre Hospital of Putuo District, Shanghai
  • Shanghai Tenth People's Hospital
  • Yangpu Hospital, Tongji University
  • Second Hospital Affiliated to Shantou Medical University
  • Shengjing Hospital of China Medical University
  • Siping Central People's Hospital
  • The First Affiliated Hospital of Soochow University
  • Nankai University Affiliated Hospital
  • The 2nd Hospital of Tianjin Medical University
  • Tianjin Medical University General Hospital
  • Renmin Hospital of Wuhan University
  • First Affiliated Hospital of Xiamen University
  • the first people hospital of Yue Yang
  • Affiliated Hospital of Jiangsu University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

linagliptin

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment
Percentage change from baseline, that is, [[(HbA1c after 24 weeks of treatment) - (HbA1c at baseline)] / (HbA1c at baseline)] *100%, where baseline refers to the last observation prior to the start of randomised study drug, including the observation prior to the placebo run-in.

Secondary Outcome Measures

Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment
Change from baseline in Fasting plasma glucose (FPG) after 24 weeks of treatment.
Change From Baseline in 2-hour (2-h) Postprandial Plasma Glucose (PPG) After 24 Weeks of Treatment
Change from baseline in 2-hour (2-h) postprandial plasma glucose (PPG) after 24 weeks of treatment.
Percentage of Participants With HbA1c on Treatment <7.0 Percentage (%) After 24 Weeks of Treatment
Percentage of participants with HbA1c on treatment <7.0 percentage (%) after 24 weeks of treatment. Participants with baseline HbA1c <7.0% were excluded from the analysis.
Percentage of Participants With HbA1c on Treatment < 6.5% After 24 Weeks of Treatment
Percentage of participants with HbA1c on treatment < 6.5% after 24 weeks of treatment. Participants with baseline HbA1c <6.5% were excluded from the analysis.
Percentage of Participants With HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment
Percentage of participants with HbA1c lowering by at least 0.5% after 24 weeks of treatment.
Percentage of Participants With Any Investigator-defined Hypoglycaemic Adverse Event (AE) With Plasma Glucose (PG) ≤70 mg/dL
Incidence of investigator-reported hypoglycaemic events confirmed by a measured blood glucose ≤70 mg/dL (≤3.9 Millimoles Per Litre (mmol/L)). Severe hypoglycaemic AE = hypoglycaemic event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.
Percentage of Participants With Any Severe Hypoglycaemic AE
Incidence of severe hypoglycaemic events (requiring active assistance by another person, or fatal). Severe hypoglycaemic AE = hypoglycaemic event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.

Full Information

First Posted
August 30, 2016
Last Updated
March 24, 2020
Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT02897349
Brief Title
Linagliptin Add-on to Insulin Background Therapy
Official Title
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Linagliptin, Administered Orally Once Daily, in Combination With Insulin Therapy for 24 Weeks in Chinese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
September 30, 2016 (Actual)
Primary Completion Date
January 11, 2019 (Actual)
Study Completion Date
January 18, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company

4. Oversight

5. Study Description

Brief Summary
To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
206 (Actual)

8. Arms, Groups, and Interventions

Arm Title
linagliptin
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Type
Drug
Intervention Name(s)
linagliptin
Intervention Type
Drug
Intervention Name(s)
background therapy
Intervention Description
insulin with or without metformin
Primary Outcome Measure Information:
Title
Percentage Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment
Description
Percentage change from baseline, that is, [[(HbA1c after 24 weeks of treatment) - (HbA1c at baseline)] / (HbA1c at baseline)] *100%, where baseline refers to the last observation prior to the start of randomised study drug, including the observation prior to the placebo run-in.
Time Frame
Baseline and week 24
Secondary Outcome Measure Information:
Title
Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment
Description
Change from baseline in Fasting plasma glucose (FPG) after 24 weeks of treatment.
Time Frame
Baseline and week 24
Title
Change From Baseline in 2-hour (2-h) Postprandial Plasma Glucose (PPG) After 24 Weeks of Treatment
Description
Change from baseline in 2-hour (2-h) postprandial plasma glucose (PPG) after 24 weeks of treatment.
Time Frame
Baseline and week 24
Title
Percentage of Participants With HbA1c on Treatment <7.0 Percentage (%) After 24 Weeks of Treatment
Description
Percentage of participants with HbA1c on treatment <7.0 percentage (%) after 24 weeks of treatment. Participants with baseline HbA1c <7.0% were excluded from the analysis.
Time Frame
24 weeks
Title
Percentage of Participants With HbA1c on Treatment < 6.5% After 24 Weeks of Treatment
Description
Percentage of participants with HbA1c on treatment < 6.5% after 24 weeks of treatment. Participants with baseline HbA1c <6.5% were excluded from the analysis.
Time Frame
24 weeks
Title
Percentage of Participants With HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment
Description
Percentage of participants with HbA1c lowering by at least 0.5% after 24 weeks of treatment.
Time Frame
24 weeks
Title
Percentage of Participants With Any Investigator-defined Hypoglycaemic Adverse Event (AE) With Plasma Glucose (PG) ≤70 mg/dL
Description
Incidence of investigator-reported hypoglycaemic events confirmed by a measured blood glucose ≤70 mg/dL (≤3.9 Millimoles Per Litre (mmol/L)). Severe hypoglycaemic AE = hypoglycaemic event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.
Time Frame
24 weeks
Title
Percentage of Participants With Any Severe Hypoglycaemic AE
Description
Incidence of severe hypoglycaemic events (requiring active assistance by another person, or fatal). Severe hypoglycaemic AE = hypoglycaemic event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Diagnosis of type 2 diabetes mellitus prior to informed consent. Chinese male or female patients who are pre-treated with insulin alone or in combination with metformin: With maximum insulin dose of <= 1 unit/kg/day. Acceptable basal insulins could be insulin glargin, insulin detemir or NPH (neutral protamin hagedorn) insulin with duration of action up to 24 h; acceptable pre-mixed insulins could be preparations with 25/75 or 30/70 ratio, with once or twice daily posology only. The total insulin dose should not be changed by more than 10% of the baseline value within the 12 weeks prior to randomisation (Visit 3). Both human insulin & insulin analogue are accepted. If the patient is taking metformin, stable dose (at least 1500 mg daily) must be maintained for at least 12 weeks without dose adjustments prior to randomisation (Visit 3). HbA1c fulfills the following criteria: >= 7.5 % to <= 10.0 % at Visit 1. Age >= 18 years at Visit 1. BMI <= 45 kg/m2 (Body Mass Index) at Visit 1. Women of childbearing potential must be ready and able to use highly effective methods of birth control per ICH (International Conference on Harmonisation) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Signed and dated written informed consent by date of Visit 1 in accordance with ICH-GCP (Good Clinical Practice) and local legislation Exclusion criteria: Uncontrolled hyperglycaemic with a glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day). Any other antidiabetic drug within 3 months prior to informed consent except those defined as background treatment via inclusion criterion 2. Acute coronary syndrome (non-STEMI (ST Segment Elevation Myocardial Infarction), STEMI and unstable angina pectoris), stroke or TIA (Transient ischemic attack) within 3 months prior to informed consent. Indication of liver disease, defined by serum levels of either ALT (Alanine aminotransferase) (SGPT (serum glutamic pyruvate transaminase )), AST (Aspartate aminotransferase) (SGOT (serum glutamic-oxaloacetic transaminase)), or alkaline phosphatase above 3 × upper limit of normal (ULN (upper limit of normal)) as determined during screening and/or run-in phase. Any contraindications to metformin according to the local label for those patients that enter the study with metformin therapy as provided in ISF (Investigator Site File). Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years. Blood dyscrasias or any disorders causing hemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anemia). Known hypersensitivity or allergy to the investigational product or its recipients. Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM (Type 2 diabetes mellitus). Women who are pregnant, nursing, or who plan to become pregnant while in the trial. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator. Participation in another trial with an investigational drug within 2 months prior to informed consent or previous enrolment in this trial. Any other clinical condition that would jeopardize patient's safety while participating in this clinical trial in the opinion of the investigator.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
China-Japan Friendship Hospital
City
Beijing
ZIP/Postal Code
100029
Country
China
Facility Name
Beijing Tongren Hospital
City
Beijing
ZIP/Postal Code
100730
Country
China
Facility Name
The General Hospital of Chinese People's Armed Police Forces
City
Beijing
ZIP/Postal Code
100854
Country
China
Facility Name
First Hospital of Jilin University
City
Changchun
ZIP/Postal Code
130021
Country
China
Facility Name
No.900 Hospital of PLA Joint Logistics Support Force
City
Fuzhou
ZIP/Postal Code
350025
Country
China
Facility Name
Third Affiliated Hospital of Guangzhou Medical University
City
Guangzhou
ZIP/Postal Code
510150
Country
China
Facility Name
The Affiliated Hospital of Guizhou Medical University
City
Guiyang
ZIP/Postal Code
550004
Country
China
Facility Name
The Affiliated Hospital of Hangzhou Normal University
City
Hangzhou
ZIP/Postal Code
310015
Country
China
Facility Name
General Hospital of Jinan Military Area
City
Jinan
ZIP/Postal Code
250000
Country
China
Facility Name
Nanjing First Hospital
City
Nanjing
ZIP/Postal Code
210006
Country
China
Facility Name
The affiliated hospital of medicalcollege qingdao university
City
Qingdao
ZIP/Postal Code
266005
Country
China
Facility Name
Centre Hospital of Putuo District, Shanghai
City
Shanghai
ZIP/Postal Code
200062
Country
China
Facility Name
Shanghai Tenth People's Hospital
City
Shanghai
ZIP/Postal Code
200072
Country
China
Facility Name
Yangpu Hospital, Tongji University
City
Shanghai
ZIP/Postal Code
200090
Country
China
Facility Name
Second Hospital Affiliated to Shantou Medical University
City
Shantou
ZIP/Postal Code
515041
Country
China
Facility Name
Shengjing Hospital of China Medical University
City
Shengyang
ZIP/Postal Code
110072
Country
China
Facility Name
Siping Central People's Hospital
City
Siping
ZIP/Postal Code
136000
Country
China
Facility Name
The First Affiliated Hospital of Soochow University
City
Suzhou
ZIP/Postal Code
215006
Country
China
Facility Name
Nankai University Affiliated Hospital
City
Tianjin
ZIP/Postal Code
300000
Country
China
Facility Name
The 2nd Hospital of Tianjin Medical University
City
Tianjin
ZIP/Postal Code
300000
Country
China
Facility Name
Tianjin Medical University General Hospital
City
Tianjin
ZIP/Postal Code
30052
Country
China
Facility Name
Renmin Hospital of Wuhan University
City
Wuhan
ZIP/Postal Code
430060
Country
China
Facility Name
First Affiliated Hospital of Xiamen University
City
Xiamen
ZIP/Postal Code
361003
Country
China
Facility Name
the first people hospital of Yue Yang
City
Yueyang
ZIP/Postal Code
414000
Country
China
Facility Name
Affiliated Hospital of Jiangsu University
City
Zhenjiang
ZIP/Postal Code
212013
Country
China

12. IPD Sharing Statement

Links:
URL
http://trials.boehringer-ingelheim.com/
Description
Related Info

Learn more about this trial

Linagliptin Add-on to Insulin Background Therapy

We'll reach out to this number within 24 hrs